創薬技術市場：技術別、薬剤タイプ別、エンドユーザー別-2025～2030年の世界予測

創薬技術市場は、2023年に645億7,000万米ドルと評価され、2024年には713億2,000万米ドルに達すると予測され、CAGR 10.64％で成長し、2030年には1,310億8,000万米ドルに達すると予測されています。

創薬技術には、さまざまな病状に対処するための実行可能な治療候補を特定するための中心的な科学的・計算的手法、機器、戦略が幅広く含まれています。これらの技術は、慢性疾患の罹患率の上昇や新たな病原体の出現の中で、より効果的で、より安全で、より的を絞った治療に対する需要の高まりから不可欠なものとなっています。その応用範囲は、高性能・スクリーニングやゲノミクスからバイオインフォマティクスやAI主導のドラッグ・デザインにまで及び、それぞれが製薬、バイオテクノロジー、学術研究機関において重要な役割を果たしています。最終用途の範囲には、製薬会社、受託研究機関、学術機関が含まれ、いずれもコストを最小限に抑えながら医薬品開発サイクルを加速しようとしています。主要成長促進要因としては、計算ツール、ビッグデータ分析、AIの進歩により、薬剤の有効性と毒性のより正確な予測が可能になったことや、個別化医療の統合が進んでいることが挙げられます。さらに、官民間の協力関係の強化は、技術革新と投資のための環境を促進します。しかし、研究開発に関連する高コスト、厳しい規制状況、創薬と市場開拓のペースを妨げる知的財産権に関する懸念など、市場の成長は大きな課題に直面しています。AIと機械学習を活用した予測分析で医薬品候補の評価を効率化し、生成AIで新規化合物の合成を行うことにビジネス機会があります。新たな医療ニーズを持つ未開拓市場の開拓は、新たな成長の道を記載しています。CRISPRをはじめとする遺伝子編集技術の革新は、治療戦略を変革し、画期的な治療法を生み出す可能性を秘めています。市場は、急速な技術進歩に伴う激しい競争状態にあり、企業が競合を維持するためには、継続的な戦略的適応が必要となります。企業は、このダイナミックで複雑な市場環境で成功するために、最先端の研究開発への投資を優先し、戦略的提携を育み、進化する規制の変化に適応すべきです。

市場力学：急速に進化する創薬技術市場の主要市場洞察を公開

創薬技術市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患や感染症の治療における低分子医薬品や生物製剤の使用拡大
  • 創薬・開発に対する政府の支援策と投資
  • 世界中のCDMOによる創薬技術の急速な採用
• 市場抑制要因
  • 創薬開発の初期設定コストが高い
• 市場機会
  • 創薬プラットフォームの継続的な技術進歩
  • 新規創薬分子開発のための研究開発費の増加
• 市場課題
  • 厳しい規制環境と熟練専門家の不足

ポーターのファイブフォース：創薬技術市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：創薬技術市場における外部からの影響の把握

外部マクロ環境要因は、創薬技術市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：創薬技術市場における競合情勢の把握

創薬技術市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：創薬技術市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、創薬技術市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：創薬技術市場における成功への道筋を描く

創薬技術市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患や感染症の治療における低分子医薬品や生物製剤の使用増加
    • 医薬品の発見と開発に対する政府の支援的な取り組みと投資
    • 世界中のCDMOによる創薬技術の急速な採用
  • 抑制要因
    • 医薬品の発見と開発のための初期設定コストが高い
  • 機会
    • 創薬プラットフォームにおける継続的な技術進歩
    • 新規薬剤分子の開発のための研究開発費の増加
  • 課題
    • 厳しい規制環境と熟練した専門家の不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 創薬技術市場：技術別

• イントロダクション
• バイオ分析機器
• バイオチップ
• バイオインフォマティクス
• コンビナトリアルケミストリー
• ゲノミクス
• 高性能スクリーニング
• ナノ技術
• 薬理ゲノム学
• RNA干渉

第7章 創薬技術市場：薬剤タイプ別

• イントロダクション
• 生物製剤
• 低分子医薬品

第8章 創薬技術市場：エンドユーザー別

• イントロダクション
• バイオ医薬品企業
• バイオテクノロジー企業
• 製薬会社
• 研究機関

第9章 南北アメリカの創薬技術市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の創薬技術市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの創薬技術市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • 医薬品開発技術企業のArisGlobalがAmplexor Life Sciencesの買収を完了
  • Luxna、Servierとの創薬研究に関する協力契約を発表
  • Iktos、AI事業拡大のため1,550万ユーロ（1,634万米ドル）を調達創薬技術
  • Charles River、医薬品発見技術企業を5,000万米ドルで買収
  • BioNTech、AI創薬スタートアップInstadeepを3億6,200万ポンド（4億4,015万米ドル）で買収へ
  • 日本のスタートアップ企業Veritas In SilicoがMRNAを標的とした低分子医薬品の発見で新たな提携を締結
  • AblexisとAlivaMab Discovery Servicesが抗体医薬品の発見とエンジニアリング能力の拡大を発表
  • CytoReason、医薬品の発見と開発にAIを提供するためファイザーとの提携契約の拡大を発表
  • Aurigene Discovery Technologies Limited、EQRxとの医薬品の発見、開発、商業化に関する提携を発表
  • CHARM、5,000万米ドルのシリーズA資金調達でAI創薬技術を発表
• 戦略分析と提言

企業一覧

• Abbott Laboratories, Inc.
• Agilent Technologies, Inc
• Amgen Inc.
• Applied Biosystems by Thermo FIsher Scientific
• AstraZeneca PLC
• Base Pair BIoTechnologies by Aptamer Discovery Company
• Bayer Healthcare AG
• Bio-Rad Laboratories, Inc.
• bioMerieux
• Bristol-Myers Squibb Company
• Covaris, LLC
• Curia Global, Inc.
• Elucidata Corporation
• Eurofins Advinus Private Limited
• Evotec SE
• F. Hoffmann-La Roche Ltd.
• GE Healthcare Ltd.
• Gilead Sciences, Inc.
• Hichrom Limited by VWR International
• Horiba, Ltd.
• Illumina, Inc.
• IQVIA Inc.
• Luminex Corporation by DiaSorin Group
• Merck & Co., Inc.
• Novartis AG
• Parr Instrument Company
• Pfizer Inc.
• Piramal Pharma Solutions
• Randox Laboratories Ltd.
• Revolution Medicines, Inc.
• Sanofi
• Sygnature Discovery Limited
• Syngene International Limited
• WuXi AppTec Co., Ltd.

LIST OF FIGURES

• FIGURE 1. DRUG DISCOVERY TECHNOLOGIES MARKET RESEARCH PROCESS
• FIGURE 2. DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DRUG DISCOVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DRUG DISCOVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DRUG DISCOVERY TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DRUG DISCOVERY TECHNOLOGIES MARKET DYNAMICS
• TABLE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY GENOMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 123. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. DRUG DISCOVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 153. DRUG DISCOVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2023

The Drug Discovery Technologies Market was valued at USD 64.57 billion in 2023, expected to reach USD 71.32 billion in 2024, and is projected to grow at a CAGR of 10.64%, to USD 131.08 billion by 2030.

Drug discovery technologies encompass a broad array of scientific and computational methods, instruments, and strategies central to identifying viable therapeutic candidates for addressing various medical conditions. These technologies are indispensable due to the increasing demand for more effective, safer, and more targeted treatments amidst the rising incidence of chronic diseases and the emergence of novel pathogens. Their application ranges from high-throughput screening and genomics to bioinformatics and AI-driven drug design, each playing a vital role in pharmaceutical, biotechnology, and academic research institutions. The end-use scope includes pharmaceutical companies, contract research organizations, and academic institutions, all seeking to accelerate drug development cycles while minimizing costs. Key growth drivers include the advancement of computational tools, big data analytics, and AI, enabling more precise predictions of drug efficacy and toxicity, as well as the growing integration of personalized medicine. Moreover, the increasing collaborations between public and private sectors foster conducive environments for innovation and investment. However, market growth faces significant challenges such as high costs associated with R&D, stringent regulatory landscapes, and intellectual property concerns, which can hinder the pace of drug discovery and development. Opportunities lie in leveraging AI and machine learning for predictive analytics to streamline drug candidate evaluations and generative AI for novel compound synthesis. Exploring untapped markets with emerging healthcare needs can offer new growth avenues. Innovations in CRISPR and other gene-editing technologies hold promise for transforming therapeutic strategies and creating breakthrough treatments. The market is intensely competitive with rapid technological advancement necessitating continual strategic adaptability for firms to maintain a competitive edge. Firms should prioritize investments in cutting-edge R&D, foster strategic alliances, and adapt to evolving regulatory changes to thrive in this dynamic and complex market environment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug Discovery Technologies Market

The Drug Discovery Technologies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing use of small-molecular and biologics drugs to treat chronic and infectious disorders
  • Supportive government iniatives and investments for drug discovery and development
  • Rapid adoption of drug discovery technologies by CDMOs worldwide
• Market Restraints
  • High initial setup cost for drug discovery and development
• Market Opportunities
  • Ongoing technological advancements in drug discovery platforms
  • Increasing research and development expenditure for development of novel drug molecules
• Market Challenges
  • Stringent regulatory environment and limited availability of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the Drug Discovery Technologies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug Discovery Technologies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug Discovery Technologies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug Discovery Technologies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug Discovery Technologies Market

A detailed market share analysis in the Drug Discovery Technologies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug Discovery Technologies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug Discovery Technologies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug Discovery Technologies Market

A strategic analysis of the Drug Discovery Technologies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug Discovery Technologies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Inc., Agilent Technologies, Inc, Amgen Inc., Applied Biosystems by Thermo FIsher Scientific, AstraZeneca PLC, Base Pair Biotechnologies by Aptamer Discovery Company, Bayer Healthcare AG, Bio-Rad Laboratories, Inc., bioMerieux, Bristol-Myers Squibb Company, Covaris, LLC, Curia Global, Inc., Elucidata Corporation, Eurofins Advinus Private Limited, Evotec SE, F. Hoffmann-La Roche Ltd., GE Healthcare Ltd., Gilead Sciences, Inc., Hichrom Limited by VWR International, Horiba, Ltd., Illumina, Inc., IQVIA Inc., Luminex Corporation by DiaSorin Group, Merck & Co., Inc., Novartis AG, Parr Instrument Company, Pfizer Inc., Piramal Pharma Solutions, Randox Laboratories Ltd., Revolution Medicines, Inc., Sanofi, Sygnature Discovery Limited, Syngene International Limited, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Drug Discovery Technologies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Bioanalytical Instruments, Biochips, Bioinformatics, Combinatorial Chemistry, Genomics, High Throughput Screening, Nanotechnology, Pharmacogenomics, and RNA interference.
• Based on Drug Type, market is studied across Biologic Drugs and Small-molecule Drugs.
• Based on End User, market is studied across Biopharmaceutical Companies, Biotech Companies, Pharmaceutical Companies, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing use of small-molecular and biologics drugs to treat chronic and infectious disorders
    • 5.1.1.2. Supportive government iniatives and investments for drug discovery and development
    • 5.1.1.3. Rapid adoption of drug discovery technologies by CDMOs worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. High initial setup cost for drug discovery and development
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing technological advancements in drug discovery platforms
    • 5.1.3.2. Increasing research and development expenditure for development of novel drug molecules
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory environment and limited availability of skilled professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Drug Discovery Technologies Market, by Technology

• 6.1. Introduction
• 6.2. Bioanalytical Instruments
• 6.3. Biochips
• 6.4. Bioinformatics
• 6.5. Combinatorial Chemistry
• 6.6. Genomics
• 6.7. High Throughput Screening
• 6.8. Nanotechnology
• 6.9. Pharmacogenomics
• 6.10. RNA interference

7. Drug Discovery Technologies Market, by Drug Type

• 7.1. Introduction
• 7.2. Biologic Drugs
• 7.3. Small-molecule Drugs

8. Drug Discovery Technologies Market, by End User

• 8.1. Introduction
• 8.2. Biopharmaceutical Companies
• 8.3. Biotech Companies
• 8.4. Pharmaceutical Companies
• 8.5. Research Institutes

9. Americas Drug Discovery Technologies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Drug Discovery Technologies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Drug Discovery Technologies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Drug Development Technology player ArisGlobal Completes Acquisition of Amplexor Life Sciences.
  • 12.3.2. Luxna Announces Collaboration Agreement for Drug Discovery Research with Servier
  • 12.3.3. Iktos Raises €15.5M (USD 16.34 million) to Expand AI Drug Discovery Technologies
  • 12.3.4. Charles River Secures USD 50 Million Acquisition of Drug Discovery Tech Company.
  • 12.3.5. BioNTech to Acquire Ai Drug Discovery Start-Up Instadeep for £362m (USD 440.15 Million)
  • 12.3.6. Japanese Startup Veritas In Silico Inks New Partnership For Mrna-Targeted Small Molecule Drug Discovery
  • 12.3.7. Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities
  • 12.3.8. CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development
  • 12.3.9. Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
  • 12.3.10. CHARM Launches AI Drug Discovery Technology With USD 50 Million Series A Financing
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories, Inc.
• 2. Agilent Technologies, Inc
• 3. Amgen Inc.
• 4. Applied Biosystems by Thermo FIsher Scientific
• 5. AstraZeneca PLC
• 6. Base Pair Biotechnologies by Aptamer Discovery Company
• 7. Bayer Healthcare AG
• 8. Bio-Rad Laboratories, Inc.
• 9. bioMerieux
• 10. Bristol-Myers Squibb Company
• 11. Covaris, LLC
• 12. Curia Global, Inc.
• 13. Elucidata Corporation
• 14. Eurofins Advinus Private Limited
• 15. Evotec SE
• 16. F. Hoffmann-La Roche Ltd.
• 17. GE Healthcare Ltd.
• 18. Gilead Sciences, Inc.
• 19. Hichrom Limited by VWR International
• 20. Horiba, Ltd.
• 21. Illumina, Inc.
• 22. IQVIA Inc.
• 23. Luminex Corporation by DiaSorin Group
• 24. Merck & Co., Inc.
• 25. Novartis AG
• 26. Parr Instrument Company
• 27. Pfizer Inc.
• 28. Piramal Pharma Solutions
• 29. Randox Laboratories Ltd.
• 30. Revolution Medicines, Inc.
• 31. Sanofi
• 32. Sygnature Discovery Limited
• 33. Syngene International Limited
• 34. WuXi AppTec Co., Ltd.